Pulmonary fibrosis: A complication of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapy
- 15 August 1981
- Vol. 48 (4) , 909-911
- https://doi.org/10.1002/1097-0142(19810815)48:4<909::aid-cncr2820480408>3.0.co;2-6
Abstract
A pediatric patient is reported who experienced fatal progressive pulmonary fibrosis as a complication of 1,3‐bis(2‐chloroethyl)‐1‐nitrosourea (BCNU) therapy. The patient received a cumulative dosage of 1.29 g (1.72 g/m2) over a two‐year period as adjuvant therapy for a medulloblastoma. Two and one‐half years after cessation of therapy, cough, tachypnea and fatigue were noted. Progressive pulmonary insufficiency developed. Pulmonary pathologic findings included interstitial fibrosis and alveolar dysplasia. Other cases of BCNU pulmonary toxicity are cited from the medical literature.This publication has 14 references indexed in Scilit:
- Prediction of BCNU Pulmonary Toxicity in Patients with Malignant GliomasNew England Journal of Medicine, 1980
- Pulmonary fibrosis following low-dose 1,3-bis (2-chloro-ethyl)-1-nitrosourea (BCNU) therapyCancer, 1980
- Pulmonary toxicity of bischloronitrosourea:Report of a case with transient response to corticosteroid therapyCancer, 1979
- Fatal pulmonary fibrosis following 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) therapyCancer, 1978
- Pulmonary, Pleural, and Thoracic Changes Complicating ChemotherapyRadiology, 1977
- Pulmonary Fibrosis after Prolonged Therapy with 1,3-Bis (2-chloroethyl)-nitrosoureaChest, 1977
- New Antineoplastic Drugs and Their Proper UseMedical Clinics of North America, 1976
- The Spectrum of Drug-Induced Pulmonary DiseaseAnnals of Internal Medicine, 1972
- Lung Changes and Chemotherapeutic Agents in ChildhoodAmerican Journal of Diseases of Children, 1970
- Central nervous system leukemia and solid tumors of childhood:Treatment with 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU)Cancer, 1966